Shauryan International Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Shauryan International Pharmaceutical Export Portfolio Dataset — 2 Products, $32.3K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Shauryan International — Pharmaceutical Exporter Profile (2026) | 2 Products, $32.3K Trade | TransData Nexus

Shauryan International

Indian Pharmaceutical Exporter · Ayurvedic & Herbal Products Specialist · $32.3K Total Trade · DGFT Verified

Shauryan International is an Indian pharmaceutical exporter with a total trade value of $32.3K across 2 products in 1 therapeutic categories. Based on 68 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Kwatha ($27.5K), Gutika ($4.8K), .

Shauryan International — Export Portfolio & Destination Treemap

Shauryan International pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Shauryan International? — Company Overview & Market Position

Shauryan International is an Indian pharmaceutical exporter specializing in Ayurvedic and herbal products. Established in 2017, the company is headquartered in New Delhi, India. It operates as a privately held entity, with ownership details not publicly disclosed. The Corporate Identification Number (CIN) for Shauryan International is U21001MP2024PTC070403, indicating its registration in Madhya Pradesh. The company has an authorized share capital of ₹10,00,000 and a paid-up capital of ₹1,00,000. Specific revenue figures and employee count are not publicly available. The official website of Shauryan International is not provided in the available sources.

What Does Shauryan International Export? — Product Portfolio Analysis

Top Products by Export Value

1Kwatha$27.5K 2Gutika$4.8K

Shauryan International Therapeutic Categories — 1 Specializations

Product Portfolio — Top 2 by Export Value

Shauryan International exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Kwatha	Ayurvedic & Herbal Products	$27.5K	63	5.1%	7
2	Gutika	Ayurvedic & Herbal Products	$4.8K	5	3.9%	7

Shauryan International exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $32.3K. The top category is Ayurvedic & Herbal Products (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Shauryan International — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Shauryan International's manufacturing facilities are located in Barwala, Haryana, India. The plant specializes in the production of various pharmaceutical forms, including tablets, capsules, soft gels, syrups, oral drops, injectables, ointments, and betalactams. The facility is equipped to handle large-scale commercial supply within the pharmaceutical industry, ensuring consistent delivery to meet global standards. Specific production capacities are not publicly disclosed.

3Key Leadership

The key leadership of Shauryan International includes:

Mr. Shaurya Rawat: CEO

Mr. Ashish Goel: Contact Person

Detailed information about other executives, such as the Chief Financial Officer (CFO), is not publicly available.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Shauryan International Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Shauryan International has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports pharmaceutical products to countries such as Latvia, Poland, Lithuania, Kazakhstan, and Italy. Specific regulatory filings, approvals, and market access statuses in these regions are not publicly disclosed.

2Emerging Markets

Shauryan International has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's focus on Ayurvedic and herbal products aligns with the growing demand for natural and traditional medicines in these regions. While the company has not publicly disclosed WHO prequalification status, its product offerings may enable access to these markets.

3Geographic Strategy

Shauryan International's export data indicates a concentration in specific markets, with significant exports to Latvia, Poland, and Lithuania. This suggests a strategic focus on certain European markets. The company's portfolio concentration, with top products accounting for 100% of exports, indicates a focused product strategy. Diversification into additional therapeutic categories and geographic regions could mitigate concentration risks and support sustainable growth.

Shauryan International — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Shauryan International's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data does not indicate direct exports to the United States, suggesting limited or no current market presence in the U.S.

2WHO & EU GMP

Information regarding Shauryan International's WHO prequalification status, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly disclosed. The company's export data does not provide insights into compliance with these international standards.

3CDSCO & Indian Regulatory

Shauryan International's manufacturing facility is located in Barwala, Haryana, India. Specific details regarding approvals from the Central Drugs Standard Control Organisation (CDSCO), state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available. The company's export data does not provide insights into compliance with Indian regulatory requirements.

Shauryan International — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Shauryan International operates in the Ayurvedic and herbal pharmaceutical sector, facing competition from both domestic and international companies. While specific competitors are not identified in the available data, the company's focus on Ayurvedic and herbal products positions it in a niche market segment. The company's export data indicates a concentration in specific European markets, suggesting a targeted approach to market entry.

2Key Differentiators

Shauryan International's key differentiators include its specialization in Ayurvedic and herbal products, catering to the growing global demand for natural and traditional medicines. The company's manufacturing facility in Barwala, Haryana, is equipped to produce a wide range of pharmaceutical forms, ensuring flexibility and responsiveness to market needs.

3Strategic Position

Shauryan International's current strategic direction focuses on exporting Ayurvedic and herbal pharmaceutical products to select international markets. The company's export data indicates a concentration in specific European countries, suggesting a targeted market entry strategy. Future strategic initiatives may include diversification into additional therapeutic categories, geographic expansion, and compliance with international regulatory standards to enhance global market presence.

Buyer Due Diligence Brief — Evaluating Shauryan International as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Shauryan International has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $32,000 USD across 68 shipments. The company's portfolio is concentrated in two products, Kwatha and Gutika, indicating a focused product strategy. The company's export data suggests reliability in fulfilling international orders, with a market share of 5.1% for Kwatha and 3.9% for Gutika.

2Certifications to Verify

Importers should verify the following certifications when considering Shauryan International as a supplier:

FDA Registration: To ensure compliance with U.S. regulatory standards.

WHO-GMP Certification: To confirm adherence to World Health Organization Good Manufacturing Practices.

EU GMP Certification: To verify compliance with European Union Good Manufacturing Practices.

Frequently Asked Questions — Shauryan International

How many pharmaceutical products does Shauryan International export from India?

Shauryan International exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Kwatha ($27.5K), Gutika ($4.8K). Total export value is $32.3K.

What is Shauryan International's total pharmaceutical export value?

Shauryan International's total pharmaceutical export value is $32.3K, based on 68 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Shauryan International cover?

Shauryan International exports across 1 therapeutic categories. The largest are Ayurvedic & Herbal Products (100.0%, 2 products).

Get Full Shauryan International Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.